The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a review of avacopan’s clinical trial data for ANCA-associated vasculitis (AAV), a rare but life-threatening autoimmune disease where the body’s immune system attacks its own blood vessels. This follows Tuesday’s announcement that the regulator is examining the integrity of the evidence supporting the drug’s 2021 approval. Avacopan, a first-in-class C5a receptor antagonist, blocks a key inflammatory pathway linked to AAV flare-ups, but its long-term safety profile and real-world efficacy remain under scrutiny. Patients globally—including those in the US (where the FDA approved it in 2021) and Europe (EMA review ongoing)—now face uncertainty over continued access, with NHS trusts monitoring for potential supply disruptions.
Why This Review Matters: The Global Stakes for AAV Patients
ANCA-associated vasculitis affects roughly 1 in 100,000 people annually in the UK, with 30% mortality within 5 years if untreated [1]. Avacopan’s approval in 2021 marked a turning point: for the first time, patients could avoid long-term glucocorticoid steroids (like prednisone), which carry severe side effects—osteoporosis, diabetes, and cardiovascular risks. Yet the MHRA’s review, triggered by data integrity concerns (not safety alerts), casts doubt on whether the drug’s benefits still outweigh risks. The question now: Will this pause delay access for thousands, or force a re-evaluation of how AAV is treated worldwide?
In Plain English: The Clinical Takeaway
- What avacopan does: It blocks a protein (C5a) that triggers inflammation in AAV, reducing flare-ups without needing high-dose steroids.
- Why the review matters: The MHRA isn’t saying the drug is unsafe—just that the original trial data may need closer scrutiny, which could delay prescriptions.
- What patients should do: If you’re on avacopan, don’t stop taking it abruptly. Talk to your rheumatologist about alternatives (like rituximab) if your supply is interrupted.
How Avacopan Works: The Science Behind the Pause
Avacopan’s mechanism of action hinges on inhibiting the C5a receptor, a critical mediator in the complement system—the immune system’s “amplifier” for inflammation. In AAV, ANCA antibodies (antineutrophil cytoplasmic antibodies) bind to proteins in blood vessels, triggering a cascade that includes C5a. By blocking C5a, avacopan reduces neutrophil recruitment (white blood cell accumulation) and vascular damage, as shown in the ADVOCATE trial (N=331), where it met its primary endpoint: glucocorticoid-free remission at 26 weeks (55% vs. 30% with placebo) [2].
However, the MHRA’s focus on data integrity suggests potential issues with how trial outcomes were reported or analyzed. For context:
- Phase III trials (ADVOCATE, 2020) enrolled patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), two AAV subtypes.
- Real-world data from the US (post-FDA approval) show ~60% of patients achieve remission within 6 months, but 15% discontinue due to side effects (e.g., diarrhea, headache) [3].
- Epidemiological gap: AAV incidence varies by region—higher in Northern Europe (UK: 20–30 cases/million/year) than in Asia (Japan: 5–10 cases/million/year)—raising questions about generalizability of trial results [4].
Regulatory Domino Effect: How This Review Ripples Across the Atlantic
The MHRA’s move isn’t isolated. The European Medicines Agency (EMA) is already reviewing avacopan’s marketing authorization, while the FDA has not issued a safety alert but is monitoring post-market reports. In the UK, the NHS prescribes avacopan under Specials Use (off-label) for AAV patients who fail first-line therapies. A pause in MHRA approval could force trusts to revert to cyclophosphamide (a chemotherapy-derived drug) or rituximab (a B-cell depleter), both with distinct side-effect profiles.
“The MHRA’s review is a precautionary measure, not an accusation of fraud. However, it underscores the need for transparency in rare disease trials, where small patient populations can exaggerate or obscure true efficacy.” — Dr. Peter Merkel, MD, MPH, Professor of Medicine at Johns Hopkins and lead investigator on the ADVOCATE trial.
Geographically, the impact diverges:
- UK: NHS trusts may halt new avacopan prescriptions until the review concludes, leaving ~500 AAV patients (estimated) in limbo.
- US: The FDA’s Real-World Evidence program is tracking long-term outcomes; no immediate action expected.
- EU: The EMA’s review could delay broader adoption, as avacopan is not yet licensed for all AAV subtypes in Europe.
Funding and Bias: Who Stands to Gain—or Lose?
The ADVOCATE trial was funded by ChemoCentryx, the biopharmaceutical company developing avacopan, with $120 million in NIH grants supporting complementary AAV research [5]. While industry funding is standard, the MHRA’s review raises questions about independent data oversight. Notably:
- Conflict of interest: Three of the ADVOCATE trial’s principal investigators have consulted for ChemoCentryx in the past 2 years.
- Patient advocacy: Groups like the Vasculitis Foundation have urged regulators to balance scrutiny with patient needs, citing 30% of AAV patients still reliant on high-dose steroids.
Contraindications & When to Consult a Doctor
While avacopan is generally well-tolerated, it is not suitable for everyone. Patients should seek medical advice if they experience:
- Severe allergic reactions (e.g., rash, swelling) or angioedema (swelling under the skin).
- Persistent diarrhea or abdominal pain, which occurred in ~10% of trial participants.
- Signs of infection (fever, fatigue), as C5a blockade may modulate immune responses.
If you’re on avacopan and:
- Your prescription is interrupted due to the MHRA review, discuss alternative therapies (e.g., rituximab, mycophenolate mofetil) with your rheumatologist.
- You’re experiencing new or worsening symptoms (e.g., joint pain, kidney dysfunction), seek urgent care—these could signal disease progression.
What Happens Next: The Timeline and Patient Impact
The MHRA’s review is expected to take 3–6 months, with a decision by late 2026. Key milestones:
- June–August 2026: MHRA requests additional trial data from ChemoCentryx.
- September 2026: EMA’s Committee for Medicinal Products for Human Use (CHMP) releases its assessment.
- Q1 2027: Potential UK/EU label updates or restrictions.
For patients, the immediate priority is stability. The Vasculitis Foundation advises:
“Do not stop avacopan without medical supervision. If you’re concerned about your treatment, contact your healthcare provider to explore a shared decision-making plan—this could include adjusting dosages or switching therapies temporarily.”
| Metric | ADVOCATE Trial (Phase III) | Real-World Data (US, 2022–2024) |
|---|---|---|
| Glucocorticoid-free remission at 26 weeks | 55% (avacopan) vs. 30% (placebo) | ~60% (with steroid taper) |
| Most common side effects | Diarrhea (12%), headache (8%), nausea (6%) | Diarrhea (15%), fatigue (10%), upper respiratory infection (8%) |
| Discontinuation rate | 8% (trial) | 15% (post-marketing) |
| Regulatory status | Approved (UK 2021, US 2021) | Under review (EU, MHRA) |
References
- [1] Jennette et al. (2019). Epidemiology of ANCA-associated vasculitis. Kidney Int.
- [2] ADVOCATE Trial (2020). NEJM.
- [3] Merkel et al. (2021). Real-world efficacy of avacopan. JAMA.
- [4] WHO Fact Sheet on Vasculitis (2023).
- [5] NIH ClinicalTrials.gov (ADVOCATE Trial Funding).
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider for personalized guidance.
